Imaging with a new PET tracer in cancer patients
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
This study is testing a new imaging tool for cancer patients to see if it can find tumors better than current methods.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Fuzhou) |
| Trial ID | NCT06740240 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and effectiveness of a novel dual-targeting PET radiotracer, 68Ga-FAPI-Biotin, in patients with various types of cancer. It aims to assess the biodistribution, pharmacokinetics, and dosimetry of the tracer while comparing its diagnostic efficacy against existing imaging agents like 68Ga-FAPI and 18F-FDG. By targeting fibroblast activation protein and biotin, the study seeks to enhance tumor detection sensitivity and specificity. The findings could provide insights into the potential of this new imaging agent in clinical practice.
Who should consider this trial
Good fit: Ideal candidates include patients with various solid tumors who have confirmed histopathological findings.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved imaging techniques for better diagnosis and treatment planning in cancer patients.
How similar studies have performed: While some studies have shown promise with similar imaging approaches, this specific dual-targeting method is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Various solid tumors with available histopathological findings; Signed informed consent. Exclusion Criteria: Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
Where this trial is running
Fuzhou
- First Affiliated Hospital of Fujian Medical University — Fuzhou, China (Recruiting)
Study contacts
- Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.